Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection.
Previous in vivo studies have suggested that nucleic acid polymers (NAPs) may reduce circulating levels of HBsAg in the blood by blocking its release from infected hepatocytes and that this effect may have clinical benefit. NAP treatment, was evaluated in two clinical studies in patients with HBeAg positive chronic HBV infection. The REP 101 study examined REP 2055 monotherapy in 8 patients and the REP 102 study examined REP 2139-Ca, in monotherapy in 12 patients, 9 of which transitioned to short term combined treatment with pegylated interferon alpha 2a or thymosin alpha 1. In both studies NAP monotherapy was accompanied by 2-7 log reductions of serum HBsAg, 3-9 log reductions in serum HBV DNA and the appearance of serum anti-HBsAg antibodies (10-1712 mIU / ml). Eight of the 9 patients transitioning to combined treatment with immunotherapy (pegylated interferon or thymosin alpha 1) in the REP 102 study experienced HBsAg loss and all 9 patients experienced substantial increases in serum anti-HBsAg antibody titers before withdrawal of therapy. For 52 weeks after removal of REP 2055 therapy, rebound of serum viremia (HBV DNA > 1000 copies / ml, HBsAg > 1IU / ml) was not observed in 3 / 8 patients. Suppression of serum virema was further maintained for 290 and 231 weeks in 2 of these patients. After withdrawal of all therapy in the 9 patients that transitioned to combination therapy in the REP 102 study, 8 patients achieved HBV DNA < 116 copies / ml after treatment withdrawal. Viral rebound occurred over a period of 12 to 123 weeks in 7 patients but was still absent in two patients at 135 and 137 weeks of follow-up. Administration tolerability issues observed with REP 2055 were rare with REP 2139-Ca but REP 2139-Ca therapy was accompanied by hair loss, dysphagia and dysgeusia which were considered related to heavy metal exposure endemic at the trial site. These preliminary studies suggest that NAP can elicit important antiviral responses during treatment which may improve the effect of immunotherapy. NAPs may be a potentially useful component of future combination therapies for the treatment of chronic hepatitis B.


BACKGROUND
ClinicalTrials.gov NCT02646163 and NCT02646189.
Bangabandhu Sheikh Mujib Medical University, Shahbagh Road, Dhaka-1000, Bangladesh.
Mamun
M
Al-Mahtab
Replicor Inc., 6100 Royalmount Avenue, Montreal, Quebec, Canada H4P 2R2.
Michel
M
Bazinet
Replicor Inc., 6100 Royalmount Avenue, Montreal, Quebec, Canada H4P 2R2.
Andrew
A
Vaillant
D000293:Adolescent; D000328:Adult; D001459:Bangladesh; D005260:Female; D006513:Hepatitis B e Antigens / Q000097:blood*; D019694:Hepatitis B, Chronic / Q000097:blood / Q000276:immunology* / Q000628:therapy*; D022781:Hepatocytes / Q000166:cytology / Q000187:drug effects; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009696:Nucleic Acids / Q000627:therapeutic use*; D061214:Patient Safety; D011108:Polymers / Q000627:therapeutic use*; D000077596:Thymalfasin; D013947:Thymosin / Q000031:analogs & derivatives / Q000627:therapeutic use; D055815:Young Adult
D006513:Hepatitis B e Antigens; D016898:Interferon-alpha; D009696:Nucleic Acids; D011108:Polymers; D013947:Thymosin; D000077596:Thymalfasin